Beth Hoffman, PhD
At Origami Therapeutics, Dr. Hoffman is creating a new approach to drug discovery for neurodegenerative diseases, leveraging her experience from 20 years of CNS drug discovery and from discovering transformational therapies for Cystic Fibrosis (CF). Prior to Origami, she was a Research & Development executive at Vertex Pharmaceuticals, Amgen and Eli Lilly. She made major contributions to >30 programs that advanced to clinical trials and to four marketed drugs for CF. Dr. Hoffman received her AB in Molecular Biology from Wellesley College and a PhD in Cell Biology from the Johns Hopkins University. She was Chief of the Molecular Pharmacology Unit at the National Institute of Mental Health, Bethesda, MD and was awarded the Prize of the Anna Monika Foundation. Dr. Hoffman serves on the Board of Directors for Biofrontera Inc. (NASDAQ: BFRI), the Scientific Advisory Board for the Tau Consortium and the National Board of Trustees for the Huntington’s Disease Society of America.